275 related articles for article (PubMed ID: 29499272)
1. Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs.
Klein LM; Cozzi NV; Daley PF; Brandt SD; Halberstadt AL
Neuropharmacology; 2018 Nov; 142():231-239. PubMed ID: 29499272
[TBL] [Abstract][Full Text] [Related]
2. Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.
Cozzi NV; Daley PF
Bioorg Med Chem Lett; 2016 Feb; 26(3):959-964. PubMed ID: 26739781
[TBL] [Abstract][Full Text] [Related]
3. Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives.
Brandt SD; Kavanagh PV; Dowling G; Talbot B; Westphal F; Meyer MR; Maurer HH; Halberstadt AL
Drug Test Anal; 2017 Jan; 9(1):115-126. PubMed ID: 27100373
[TBL] [Abstract][Full Text] [Related]
4. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species.
Halberstadt AL; Chatha M; Klein AK; Wallach J; Brandt SD
Neuropharmacology; 2020 May; 167():107933. PubMed ID: 31917152
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC-MS, LC-MSn, and LC-HR-MS-MS.
Michely JA; Helfer AG; Brandt SD; Meyer MR; Maurer HH
Anal Bioanal Chem; 2015 Oct; 407(25):7831-42. PubMed ID: 26297461
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA).
Halberstadt AL; Klein LM; Chatha M; Valenzuela LB; Stratford A; Wallach J; Nichols DE; Brandt SD
Psychopharmacology (Berl); 2019 Feb; 236(2):799-808. PubMed ID: 30298278
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the behavioral effects of mescaline analogs using the head twitch response in mice.
Halberstadt AL; Chatha M; Chapman SJ; Brandt SD
J Psychopharmacol; 2019 Mar; 33(3):406-414. PubMed ID: 30789291
[TBL] [Abstract][Full Text] [Related]
8. Delirium due to intoxication from the novel synthetic tryptamine 5-MeO-DALT.
Jovel A; Felthous A; Bhattacharyya A
J Forensic Sci; 2014 May; 59(3):844-6. PubMed ID: 24329118
[TBL] [Abstract][Full Text] [Related]
9. Use of the head-twitch response to investigate the structure-activity relationships of 4-thio-substituted 2,5-dimethoxyphenylalkylamines.
Halberstadt AL; Luethi D; Hoener MC; Trachsel D; Brandt SD; Liechti ME
Psychopharmacology (Berl); 2023 Jan; 240(1):115-126. PubMed ID: 36477925
[TBL] [Abstract][Full Text] [Related]
10. Tolerance and cross-tolerance to head twitch behavior elicited by phenethylamine- and tryptamine-derived hallucinogens in mice.
Smith DA; Bailey JM; Williams D; Fantegrossi WE
J Pharmacol Exp Ther; 2014 Dec; 351(3):485-91. PubMed ID: 25271256
[TBL] [Abstract][Full Text] [Related]
11. Biotransformation and detectability of the new psychoactive substances N,N-diallyltryptamine (DALT) derivatives 5-fluoro-DALT, 7-methyl-DALT, and 5,6-methylenedioxy-DALT in urine using GC-MS, LC-MS
Michely JA; Brandt SD; Meyer MR; Maurer HH
Anal Bioanal Chem; 2017 Feb; 409(6):1681-1695. PubMed ID: 27933361
[TBL] [Abstract][Full Text] [Related]
12. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.
Rickli A; Moning OD; Hoener MC; Liechti ME
Eur Neuropsychopharmacol; 2016 Aug; 26(8):1327-37. PubMed ID: 27216487
[TBL] [Abstract][Full Text] [Related]
13. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines.
Blair JB; Kurrasch-Orbaugh D; Marona-Lewicka D; Cumbay MG; Watts VJ; Barker EL; Nichols DE
J Med Chem; 2000 Nov; 43(24):4701-10. PubMed ID: 11101361
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the behavioral responses induced by phenylalkylamine hallucinogens and their tetrahydrobenzodifuran ("FLY") and benzodifuran ("DragonFLY") analogs.
Halberstadt AL; Chatha M; Stratford A; Grill M; Brandt SD
Neuropharmacology; 2019 Jan; 144():368-376. PubMed ID: 30385253
[TBL] [Abstract][Full Text] [Related]
15. Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response.
Halberstadt AL; Geyer MA
Neuropharmacology; 2014 Feb; 77():200-7. PubMed ID: 24012658
[TBL] [Abstract][Full Text] [Related]
16. Effects of the 5-HT
Jaster AM; Elder H; Marsh SA; de la Fuente Revenga M; Negus SS; González-Maeso J
Psychopharmacology (Berl); 2022 Jun; 239(6):1665-1677. PubMed ID: 35233648
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT)
Kozell LB; Eshleman AJ; Swanson TL; Bloom SH; Wolfrum KM; Schmachtenberg JL; Olson RJ; Janowsky A; Abbas AI
J Pharmacol Exp Ther; 2023 Apr; 385(1):62-75. PubMed ID: 36669875
[TBL] [Abstract][Full Text] [Related]
18. Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats.
Elmore JS; Decker AM; Sulima A; Rice KC; Partilla JS; Blough BE; Baumann MH
Neuropharmacology; 2018 Nov; 142():240-250. PubMed ID: 29501528
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the Structure-Activity Relationships of Psilocybin Analogues.
Klein AK; Chatha M; Laskowski LJ; Anderson EI; Brandt SD; Chapman SJ; McCorvy JD; Halberstadt AL
ACS Pharmacol Transl Sci; 2021 Apr; 4(2):533-542. PubMed ID: 33860183
[TBL] [Abstract][Full Text] [Related]
20. The serotonin hallucinogen 5-MeO-DMT alters cortico-thalamic activity in freely moving mice: Regionally-selective involvement of 5-HT
Riga MS; Lladó-Pelfort L; Artigas F; Celada P
Neuropharmacology; 2018 Nov; 142():219-230. PubMed ID: 29221792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
